drugset / Trial / NCT00418795
Porphozym in the Treatment of Acute Attacks in AIP
RandomizedParallel-groupDouble-blindTreatment
Summary
A multi-centre, double-blind, randomized, placebo controlled, parallel group trial, investigating the efficacy and safety of Porphozym (recombinant human porphobilinogen deaminase)in the treatment of acute attacks in AIP.
Timeline
- Start
- 2003-06-11
- Primary completion
- 2006-06-20
- Completion
- 2006-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | recombinant human porphobilinogen deaminase | Protein / enzyme biologic | — | Intravenous |